vTv Therapeutics T1D KOL Breakfast

New York, October 8, 2019

Please join vTv Therapeutics (VTVT) for a KOL breakfast highlighting the Type 1 Diabetes treatment landscape and emerging therapies as treatment adjuncts to insulin. 

Date:
Tuesday, October 8th

Time:
8:00 AM EST Registration & Breakfast
8:30 AM: Presentations / Q&A
 

Location:
New York, NY 
 

For more information or to RSVP, please email mbiega@troutgroup.com

General Agenda

Introduction

Steve Holcombe, President & CEO, vTv Therapeutics

 

T1D Overview and Treatment Landscape

Kevan C. Herold, MD, CNH, Professor of Immunobiology and Internal Medicine; Deputy Director, Yale Center for Clinical Investigation, Yale University

 

T1D Patient Perspective

Esther Latres, PhD, Director, Research, JDRF

 

Treatment Adjuncts to Insulin in T1D

John B. Buse, MD, PhD, Verne S. Caviness Distinguished Professor, Chief, Division of Endocrinology; Director, Diabetes Center; Director, NC Translational and Clinical Sciences Institute; Executive Associate Dean, Clinical Research, University of North Carolina School of Medicine

 

TTP399, a Liver Selective Glucokinase Activator, Ph2 Results and Recently Presented Data at the 55th Annual Meeting of the European Association for the Study of Diabetes

Carmen Valcarce, EVP & CSO, vTv Therapeutics

 

KOLs Perspective on TTP399 Data

 

Q&A

 

Closing Remarks

Steve Holcombe, President & CEO, vTv Therapeutics

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

vTv Therapeutics, Inc. [VTVT] US$197 MM MCap
June 2019 pos­i­tive da­ta for TT­P399 as an add-on ther­a­py to in­sulin ther­a­py in a 12 week phase 1/2 trial in pa­tients with T1D. Re­sults from the se­cond part of the Ph2 study ex­pect­ed Q1 2020.&nb­sp;Re­cent­ly an­nounced the first pa­tient has been screened for the Ph2 proof of con­cept study eval­u­at­ing the safe­ty and ef­fi­ca­cy of azeli­ra­gon in pa­tients with mild Alzheimer's dis­ease and Type 2 Di­a­betes. [more in­for­ma­tion]